Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

7(87.5%)

Phase 1

1(12.5%)

8Total

Phase 2(7)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06374797Phase 2Active Not Recruiting

A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"

Role: lead

NCT04195347Phase 1Recruiting

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

Role: collaborator

NCT04345614Phase 2Completed

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

Role: lead

NCT03401190Phase 2Completed

CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS

Role: lead

NCT04661540Phase 2Terminated

A Study of Auxora in Patients With Critical COVID-19 Pneumonia

Role: lead

NCT04681066Phase 2Completed

A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Role: lead

NCT03709342Phase 2Completed

A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis

Role: lead

NCT05171920Phase 2Withdrawn

A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia

Role: lead

All 8 trials loaded